Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $5.485 million which beat the analyst consensus estimate of $1.889 million by 190.37 percent. This is a 171.27 percent increase over sales of $2.022 million the same period last year.